Risk of COVID-19 for patients with cancer

The Lancet Oncology

Volumn 21, Issue 4, 2020, Pages e181-

  Wang, Hanping ^a   Zhang, Li ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CHINA; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; EPIDEMIC; EXPOSURE; HUMAN; INFECTION RISK; LETTER; MALIGNANT NEOPLASM; PRIORITY JOURNAL; BETACORONAVIRUS; NEOPLASM; PANDEMIC; SARS CORONAVIRUS; VIRUS PNEUMONIA;

BETACORONAVIRUS; CHINA; CORONAVIRUS INFECTIONS; HUMANS; NEOPLASMS; PANDEMICS; PNEUMONIA, VIRAL; SARS VIRUS;

EID: 85082405973     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(20)30149-2     Document Type: Letter

References (4)

1. Liang, W, Guan, W, Chen, R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol, 2020 published online Feb 14. http://dx.doi.org/10.1016/S1470-2045(20)30096-6.
2. Chen, N, Zhou, M, Dong, X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395 (2020), 507–513.
3. Wang, D, Hu, B, Hu, C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020 published online Feb 7. DOI:10.1001/jama.2020.1585.
4. Wang, Y, Zhou, S, Yang, F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 5 (2019), 1008–1019.